Mr. Davidson is Co-head and Managing Director of H.I.G. BioHealth Partners where he focuses on investment opportunities in the life sciences sector. He began his career with Eli Lilly and Company, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Cardeas Pharma, Forsight Vision5, HyperBranch Medical Technology and Intact Vascular. He represented H.I.G. as a board member in several successful companies including: Alder Biopharmaceuticals (public), Novadaq Technologies (public), Salmedix (acquired) and Gemin X Pharmaceuticals (acquired).
Mr. Davidson earned his MBA from Harvard Business School and a bachelor's degree from McGill University.
Enoch focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. Enoch joined Leerink Partners from UBS where he was an Associate Director in the Global Healthcare Investment Banking Group. At Leerink Partners and UBS, Enoch gained extensive experience advising healthcare companies across the biopharmaceutical, medical devices, diagnostics, healthcare services and information technology sectors on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.
Some of the transactions Enoch has worked on include the IPOs of Eleven Biotherapeutics and Agios Pharmaceuticals, private placements and follow-on offerings for Kolltan Pharmaceuticals, Intra-Cellular Therapies, Dyax and ProQR Therapeutics, sale of Bravo Health to HealthSpring, sale of WaveMark to Cardinal Health and the leveraged recapitalization of Warner Chilcott Pharmaceuticals.
Previously, Enoch worked in the pharmaceutical industry as a Post-Doctoral Fellow in the R&D Strategy and Analytics group at Bristol-Myers Squibb and as a Pharmacist at CVS Caremark.
Enoch earned an M.B.A. from the Tuck School of Business at Dartmouth and a Doctor of Pharmacy degree from Texas Southern University.
Sami Mnaymneh is a Founder and Co-CEO of H.I.G. Capital. He has directed the firm's development since its founding in 1993 and approves all capital commitments made by H.I.G. Sami currently serves on the Board of Columbia College and on the Dean's Council of the Harvard Law School.
Prior to founding H.I.G., Sami was a Managing Director with The Blackstone Group in New York. Prior to that, he was a Vice President in the Mergers and Acquisitions department at Morgan Stanley & Co., where he devoted a significant amount of his time to leveraged buyouts, serving as senior advisor to a number of prominent private equity firms. Over the course of his career, Mr. Mnaymneh has led over 75 transactions in a wide range of industries.
Sami earned a B.A. degree, Summa Cum Laude, from Columbia University where he graduated first in his class, and subsequently received a J.D. degree and an M.B.A. degree, with honors, from Harvard Law School and Harvard Business School, respectively.
Jorge Ramirez is a Vice President at H.I.G. BioHealth Partners and focuses on development stage and growth investments in the healthcare sector.
Previously, Jorge was with ProQuest Investments, a healthcare focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling $625 million. He represented ProQuest as an observer or board member in several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX); Mevion Medical Systems; Revision Optics; Orthocon (acquired by AbyRx); and MethylGene (now, Mirati Pharmaceutics: NASDAQ: MRTX).
Jorge has also held operating roles in healthcare companies. He was the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems. He led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Jorge was a management consultant at Monitor Company focusing on commercialization strategies and M&A engagements in the healthcare and manufacturing industries.
Jorge earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an M.B.A. from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.
As Co-head and Managing Director of H.I.G. BioHealth Partners, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, Calhoun Vision, CardioFocus, Cerephex, Clarus Therapeutics, Intersection Medical and Iconic Therapeutics.
Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Sid is a Vice President at H.I.G. BioHealth Partners and focuses on development stage and growth investments in the life sciences. Sid is responsible for all aspects of the investment process.
Sid has over seven years of experience in the life sciences, across biotechnology, pharmaceuticals and medical devices. Prior to joining H.I.G., Sid was as a Consultant with The Boston Consulting Group, where he worked on merger and divestiture-related cases for large pharmaceutical clients.
Sid earned an M.B.A. from Harvard Business School, a Ph.D. from Columbia University in biomedical engineering and undergraduate degrees, summa cum laude, in biomedical engineering and economics from Rensselaer Polytechnic Institute.
Tony Tamer is a Founder and Co-CEO of H.I.G. Capital. He has directed H.I.G.'s development since its founding in 1993 and approves all capital commitments made by the firm. Tony has led a number of successful investments at H.I.G. in both the management buyouts and growth capital arenas. He has extensive experience working with, and coaching, early stage and middle-market companies. Tony is a board member of several H.I.G. portfolio companies. He currently also serves on the Dean's Council of the Harvard University Kennedy School of Government.
Prior to H.I.G., Tony was partner at Bain & Company where he developed business unit and operating strategies, implemented productivity improvement initiatives, and led acquisition and divestiture activities for a number of Fortune 500 clients. Tony has extensive operating experience. He has held marketing, engineering and manufacturing positions at Hewlett-Packard and Sprint Corporation.
Tony holds an M.B.A. degree from Harvard Business School, and a Masters degree in Electrical Engineering from Stanford University. His undergraduate degree is from Rutgers University.
As a Managing Director at H.I.G. BioHealth Partners, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. on the boards of: HyperBranch Medical Technology, Clarus Therapeutics, CardioFocus and NeuWave Medical.
Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.
Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.
Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics.
Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners. Previous board seats included Quinnova (sold to Amneal) and Tranzyme (merged with Ocera).
Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).
Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.
He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.